Home Cart Sign in  
Chemical Structure| 1807861-48-8 Chemical Structure| 1807861-48-8

Structure of ONC212
CAS No.: 1807861-48-8

Chemical Structure| 1807861-48-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ONC212 is a fluorinated ONC201 analog. It was identified as activator of an orphan GPCR GPR132 and Gαq signaling, which functions as a tumor suppressor.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ONC212

CAS No. :1807861-48-8
Formula : C24H23F3N4O
M.W : 440.46
SMILES Code : O=C1N(CC2=CC=C(C(F)(F)F)C=C2)C3=NCCN3C4=C1CN(CC5=CC=CC=C5)CC4
MDL No. :MFCD31619281
InChI Key :DFULPGUTXZTYKA-UHFFFAOYSA-N
Pubchem ID :124085867

Safety of ONC212

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H361-H372-H410
Precautionary Statements:P201-P264-P280-P301+P330+P331-P312
Class:9
UN#:3077
Packing Group:

Related Pathways of ONC212

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MOLM13 105.7 nM 72 hours Evaluate the apoptogenic effects of ONC212 in AML cells, ONC212 showed significantly enhanced apoptogenic effects compared to ONC201 PMC6874902
OCI-AML3 258.7 nM 72 hours Evaluate the apoptogenic effects of ONC212 in AML cells, ONC212 showed significantly enhanced apoptogenic effects compared to ONC201 PMC6874902
1068 human cancer cell lines 78 nM – 20 μM 72 hours Evaluate the broad-spectrum anti-tumor activity of ONC212 in various human cancer cell lines PMC5628644
HCT116-Bax−/− 0.01 μM 24 hours Evaluate the anti-tumor activity of ONC212 in TRAIL-resistant cell lines PMC5628644
HCT116 0.01 μM 12 hours and 24 hours Evaluate the signaling pathway activation of ONC212 in HCT116 cells PMC5628644
UACC-903 IC50 0.01 μM, IC25 0.005 μM 72 hours Evaluate the anti-tumor activity of ONC212 in melanoma cell lines PMC5628644
MM28, OMM1, MP46, MEL202, MP38, MEL20-06-039 0.05 μM to 1.0 μM 72 hours To evaluate the dose-dependent inhibitory effect of ONC212 on UM cell growth via MTT assay, IC50 concentrations ranged from 60 to 130 nM. PMC11589887
MEL20-06-039 0.1 μM and 0.2 μM 24 hours To evaluate the effect of ONC212 on mitochondrial respiration, results showed that ONC212 significantly inhibited basal, maximal, and spare mitochondrial respiratory capacity. PMC11589887
AsPC-1 cells 0.2 and 0.4 μmol/L 48 hours To assess the apoptotic induction of ONC212 in AsPC-1 cells, showing that treatment with 0.2 and 0.4 μmol/L ONC212 induced PARP cleavage, indicating apoptosis. PMC8419089
Pancreatic cancer cells 0.09-0.47 μmol/L 72 hours To evaluate the cytotoxic effects of ONC212 on various pancreatic cancer cell lines, showing differential sensitivity with GI50 values ranging from 0.09 to 0.47 μmol/L. PMC8419089
SF188 cells 200 nM 72 hours Induced apoptosis PMC6214769
U87 cells 200 nM 72 hours Inhibited proliferation PMC6214769
NCH421k cells 200 nM 72 hours Induced apoptosis and inhibited proliferation PMC6214769

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice GBM123 xenograft model Intraperitoneal injection 100 mg/kg Twice a week Extended host survival PMC6214769
Mice AML xenograft model Oral 50 mg/kg Twice per week for 7 weeks Evaluate the inhibitory effects of ONC212 on AML growth in vivo, ONC212 significantly inhibited AML growth and prolonged survival PMC6874902
C57/BL6 mice HT29 and HCT116p53−/− xenograft models Oral gavage 50 mg/kg - 100 mg/kg Once weekly for 5 weeks Evaluate the anti-tumor activity and safety of ONC212 in xenograft models PMC5628644
NSG mice UM liver metastasis model Oral gavage 25 mg/kg Twice weekly for 9-10 weeks To evaluate the therapeutic effect of ONC212 in UM liver metastasis models, results showed ONC212 significantly reduced tumor burden and improved survival. PMC11589887
Mice Radiation-induced esophagitis model Oral 25 mg/kg Twice weekly for 2 weeks ONC212 reduced the severity of radiation-induced esophagitis, characterized by reduced epithelial disruption and muscularis externa thickness. PMC11870730
Nude mice BxPC3 or HPAF-II xenograft model ONC212: Oral gavage; 2-DG: Intraperitoneal injection 50 mg/kg Three times per week for one week (short-term experiment) or until signs of toxicity or discomfort (long-term experiment) To evaluate the antitumor effects of ONC212 alone or in combination with 2-DG in pancreatic cancer xenograft models, showing that the combination significantly inhibited tumor growth and increased apoptosis. PMC8419089

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.35mL

2.27mL

1.14mL

22.70mL

4.54mL

2.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories